Cargando…

Functional Characteristics of C-terminal Lysine to Cysteine Mutant Form of CTLA-4Ig

CTLA-4Ig is regarded as an inhibitory agent of the T cell proliferation via blocking the costimulatory signal which is essential for full T cell activation. To improve applicability, we developed the CTLA-4Ig-CTKC in which the c-terminal lysine had been replaced by cysteine through single amino acid...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kim, Bongi, Shin, Jun-Seop, Park, Chung-Gyu
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	The Korean Association of Immunologists 2013
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3607706/ https://www.ncbi.nlm.nih.gov/pubmed/23559896 http://dx.doi.org/10.4110/in.2013.13.1.16

Ejemplares similares

A Novel Therapeutic Effect of a New Variant of CTLA4-Ig with Four Antennas That Are Terminally Capped with Sialic Acid in the CTLA4 Region
por: Piao, Yongwei, et al.
Publicado: (2022)

Human IgG is produced in a pro-form that requires clipping of C-terminal lysines for maximal complement activation
por: van den Bremer, Ewald TJ, et al.
Publicado: (2015)

Effects of CTLA4-Ig on human monocytes
por: Tono, Toshihiro, et al.
Publicado: (2017)

Proteolyzed Variant of IgG with Free C-Terminal Lysine as a Biomarker of Prostate Cancer
por: Lokshin, Anna, et al.
Publicado: (2021)

Cysteine-to-lysine transfer antibody fragment conjugation
por: Forte, Nafsika, et al.
Publicado: (2019)

Context‐Dependence of the Reactivity of Cysteine and Lysine Residues
por: Boll, Linus B., et al.
Publicado: (2022)

Functional Characterization of Human T Cell Hyporesponsiveness Induced by CTLA4-Ig
por: Rochman, Yrina, et al.
Publicado: (2015)

CTLA4-Ig treatment prevents murine experimental autoimmune encephalomyelitis
por: Cross, A.H., et al.
Publicado: (1994)

CTLA-4Ig Improves Hyperalgesia in a Mouse Model of Osteoporosis
por: Nagao, Nobuto, et al.
Publicado: (2020)

Cysteine Promoted C-Terminal Hydrazinolysis of Native Peptides and Proteins**
por: Adams, Anna L, et al.
Publicado: (2013)

Widespread occurrence of covalent lysine–cysteine redox switches in proteins
por: Rabe von Pappenheim, Fabian, et al.
Publicado: (2022)

Blood PD-1(+)TFh and CTLA-4(+)CD4(+) T cells predict remission after CTLA-4Ig treatment in early rheumatoid arthritis
por: Aldridge, Jonathan, et al.
Publicado: (2021)

CTLA4-Ig immunosuppressive activity at the level of dendritic cell/T cell crosstalk
por: Mayer, Edda, et al.
Publicado: (2013)

RGMB enhances the suppressive activity of the monomeric secreted form of CTLA-4
por: Sekiya, Takashi, et al.
Publicado: (2019)

CTLA-4 correlates with immune and clinical characteristics of glioma
por: Liu, Fangkun, et al.
Publicado: (2020)

Evolution of lysine acetylation in the RNA polymerase II C-terminal domain
por: Simonti, Corinne N, et al.
Publicado: (2015)

Traceless cysteine-linchpin enables precision engineering of lysine in native proteins
por: Reddy, Neelesh C., et al.
Publicado: (2022)

Successful Treatment of T Cell-Mediated Acute Rejection with Delayed CTLA4-Ig in Mice
por: Young, James S., et al.
Publicado: (2017)

Self in vivo production of a synthetic biological drug CTLA4Ig using a minicircle vector
por: Rim, Yeri Alice, et al.
Publicado: (2014)

Acetylation of C-terminal lysines modulates protein turnover and stability of Connexin-32
por: Alaei, Sarah R., et al.
Publicado: (2018)

Development of an intravital imaging system for the synovial tissue reveals the dynamics of CTLA-4 Ig in vivo
por: Hasegawa, Tetsuo, et al.
Publicado: (2020)

Effect of CTLA4-Ig on Obliterative Bronchiolitis in a Mouse Intrapulmonary Tracheal Transplantation Model
por: Suzuki, Yamato, et al.
Publicado: (2021)

Targeting inflammation and immune activation to improve CTLA4-Ig-based modulation of transplant rejection
por: Iglesias, Marcos, et al.
Publicado: (2022)

Cloning and identification of the CTLA-4IgV gene and functional application of vaccine in Xinjiang sheep
por: Kong, Huifang, et al.
Publicado: (2022)

Construction of CTLA-4-Ig Fusion Gene in pBudCE4.1 Expression Vector
por: Yazdanpanah-Samani, Mahsa, et al.
Publicado: (2015)

Gene and protein expression of a soluble form of CTLA-4 in a healthy dog
por: TAGAWA, Michihito, et al.
Publicado: (2017)

C-terminal α-synuclein truncations are linked to cysteine cathepsin activity in Parkinson's disease
por: McGlinchey, Ryan P., et al.
Publicado: (2019)

Both anti-TNF and CTLA4 Ig treatments attenuate the disease severity of staphylococcal dermatitis in mice
por: Na, Manli, et al.
Publicado: (2017)

Structure Prediction and Expression of Modified rCTLA4-Ig as a Blocker for B7 Molecules
por: Mahdizadeh, Hossein, et al.
Publicado: (2020)

The Janus face of N-terminal lysines in α-synuclein
por: Uceda, Ana Belén, et al.
Publicado: (2020)

Structural and functional insights into lysine acetylation of cytochrome c using mimetic point mutants
por: Márquez, Inmaculada, et al.
Publicado: (2021)

CTLA-4 CT-60 A/G and CTLA-4 1822 C/T Gene Polymorphisms in Indonesians with Type 1 Diabetes Mellitus
por: Rochmah, Nur, et al.
Publicado: (2022)

The Soluble Form of CTLA-4 from Serum of Patients with Autoimmune Diseases Regulates T-Cell Responses
por: Simone, Rita, et al.
Publicado: (2014)

The Role of the C-Terminal Lysine of S100P in S100P-Induced Cell Migration and Metastasis
por: Ismail, Thamir M., et al.
Publicado: (2021)

C-Terminal Lysine Residue of Pneumococcal Triosephosphate Isomerase Contributes to Its Binding to Host Plasminogen
por: Hirayama, Satoru, et al.
Publicado: (2023)

Phosphines are ribonucleotide reductase reductants that act via C-terminal cysteines similar to thioredoxins and glutaredoxins
por: Domkin, Vladimir, et al.
Publicado: (2014)

Self-assemble nanoparticles based on polypeptides containing C-terminal luminescent Pt-cysteine complex
por: Vlakh, E. G., et al.
Publicado: (2017)

Transplant-tolerance induction by CTLA-4Ig in liver-transplanted rats: a lesson for the treatment of autoimmune diseases?
por: Fischer, U, et al.
Publicado: (2003)

Abatacept (CTLA4Ig) treatment increases the remission rate in rheumatoid arthritis patients refractory to methotrexate treatment
por: Westhovens, R, et al.
Publicado: (2004)

CTLA4-Ig interacts with cultured synovial macrophages from rheumatoid arthritis patients and downregulates cytokine production
por: Cutolo, Maurizio, et al.
Publicado: (2009)

Cannot write session to /tmp/vufind_sessions/sess_o5siqgrjctjvu6aedkgn6t7hqb